Vaccination has been tremendously successful saving lives and preventing infections. However, the development of vaccines against global pandemics such as HIV, malaria and tuberculosis has been obstructed by several challenges. A major challenge is the lack of knowledge about the correlates and mechanisms of protective immunity. Recent advances in the application of systems biological approaches to analyse immune responses to vaccination in humans are beginning to yield new insights about mechanisms of vaccine immunity, and to define molecular signatures, induced rapidly after vaccination, that correlate with and predict vaccine induced immunity. Here, we review these advances and discuss the potential of this systems vaccinology approach in defining novel correlates of protection in clinical trials, and in infection-induced 'experimental challenge models' in humans.
Introduction
Vaccination has saved hundreds of millions of lives, and has had spectacular success in eliminating smallpox and in greatly reducing the burden of infections such as yellow fever, diphtheria, meningitis and measles. Despite this impressive record, the development of vaccines against global pandemics such as HIV, TB, malaria and dengue is faced with major challenges. Among the major scientific challenges are the difficulties in identifying the relevant antigens that can be incorporated into a vaccine. A second major challenge is in defining the quality of the immune response that confers protection against infection, and in determining the mechanisms by which the immune system mounts the protective response. The latter is crucial for evaluating which immunological parameters are stimulated by vaccination (i.e. correlates of immunogenicity), or are associated with protection against subsequent infection, as determined in clinical trials (i.e. correlates of protection). The final challenge is to devise strategies to induce protective immunity that is long lasting. Recent developments in the field of systems biology offer the tools to analyse the dynamics and interactions of all components of a biological system during vaccination. These systems-level analyses are beginning to define the molecular correlates ('signatures') of immunity and protection, and are yielding new insights into the mechanisms by which vaccines induce protective immunity [1] [2] [3] [4] . Here, we review these advances and their promise in enabling the development of vaccines against unmet medical needs.
Assessing the complexity of immune responses through systems vaccinology
The human immune system consists of an intricate network of specialized cells and organs. Vaccination or infection triggers a complex cascade of biological events, which if successful, culminates in the establishment of protective immunity and immunological memory against the pathogen. A powerful way to comprehensively dissect this complexity of immune responses is through the systems vaccinology approach [2] . This approach possesses the same essential elements of systems biology [5] , which are (i) monitoring all components of the system in response to perturbations, (ii) integration of data from multiple types and (iii) creation of mathematical models to predict the structure and behaviour of the informational system. Moreover, it requires the testing and validation of novel hypotheses and insights that may arise from it. The first step in the systems vaccinology approach is to perturb the immune system, and vaccines offer an excellent means to perturb the human immune system. In addition to their safety, vaccines permit a synchronized perturbation of the immune system in which the precise moment of perturbation is known, and the ensuing response followed from the earliest minutes to several decades after vaccination. In addition, vaccine perturbation experiments can be strictly controlled with respect to the vaccine dose and type, selection of time points for kinetics, use of adjuvants or booster doses, and targeting specific populations (figure 1). For example, several factors should be considered in the study of influenza vaccines: whether the vaccine is an inactivated vaccine given by intra-muscular injection (e.g. Fluarix ) or a cold-adapted live attenuated vaccine, administered as a nasal spray (e.g. FluMist w ); which time points to analyse (clonal expansion of plasmablasts in the blood of young adults peaks at day 7 post-trivalent influenza vaccine (TIV) vaccination [6] , whereas monocyte-and interferonrelated signatures peak at earlier time points [7] ); the use of adjuvants such as MF-59 w [8] ; which influenza strains to immunize subjects with, the seasonal ones [7, [9] [10] [11] [12] , or specific strains such as the 2009 H1N1 pandemics strain [11] and the avian-origin strains [13, 14] ; and, finally, the population target, which may include those with suboptimal responses or from different age groups, such as children [15] , elderly or immunocompromised patients.
The next step is to use large-scale techniques for molecular profiling of tissues and cells from human vaccinees [7, 16, 17] . The tool kit accessible to modern immunologists includes a broad range of 'omics' technologies, such as high-throughput sequencing of DNA (DNA-seq), RNA (RNA-seq) or transcription factor binding sites (chromatin immunoprecipitation, ChIP-seq) [18] , microarrays [7, [9] [10] [11] 16, 17, 19] , high-resolution mass-spectrometry proteomics/metabolomics [20] , CyTOF mass cytometer [21] and genome-wide RNAi screening [22] . It is essential that the data obtained from these techniques are integrated or associated with data obtained from 'conventional' immunological assays, such as ELISA, ELISpot, FACS, and neutralization assays. These assays enable quantitative and qualitative assessment of immune status and responses, and therefore can be useful for correlation analyses or as endpoints in predictive analyses.
The third step is to generate mathematical models from the molecular snapshots of cells and tissues that explain or predict the structure and behaviour of the system being perturbed. There are a myriad of modelling frameworks that can be applied to these purposes (reviewed in [23] ), which range from simple linear regression models to advanced and computationally expensive feature selection methods for identifying predictive signatures [24] . Structure, for example, can be assessed by computational deconvolution models, which can extract information of specific cell populations directly from data derived from heterogeneous samples (e.g. blood tissue, peripheral blood mononuclear cells (PBMCs) or lymph nodes) [25] . Network modelling in turn provides a powerful way to uncover the organizing principles and regulatory elements of cellular networks [26] , and how these networks modulate immunological responses to vaccination [17, 27] .
It is critical that predictive signatures identified on one dataset be tested on independent datasets. Including independent cohorts of vaccinees (from independent vaccine studies ideally performed at a different time from the initial study) provides the means to test and to validate the robustness of the predictive signatures of vaccine immunogenicity [7, 16, 28] , and allow the discovery of potential molecular mechanisms of vaccination [29, 30] .
The proof of concept of this systems vaccinology approach originates from studies on the yellow fever YF-17D vaccine [16, 19] . This live attenuated virus vaccine [31] is among the most effective vaccines made, and has been administered to more than 600 million people worldwide. It induces polyvalent humoral and cell-mediated immune responses [32, 33] , and confers protection to more than 90% of vaccinees [32] . A single immunization is known to confer protection that lasts several decades. Querec et al. [16] assessed the global expression changes in the PBMCs of YF-17D vaccinees during the first week to vaccination, and identified gene signatures that predict the magnitude of CD8þ T cell and antibody immunity induced several weeks later. Gaucher et al. [19] used multiparametric flow cytometry and genome-wide transcription profiling to analyse the modulation of genes associated with multilineage and polyfunctional cellular responses to YF-17D vaccination. Both studies demonstrated that the strong induction of innate immunity by yellow fever vaccine is mediated by type I interferon, inflammasome and complement genes [16, 19] .
Because of these studies, we and others have been using these iterative cycles of perturbations and high-throughput biology to investigate the molecular signatures induced by a broad range of vaccines (including yellow fever, influenza, meningococcal, adenovirus, shingles, pneumococcal, malaria, tularaemia, rotavirus), with a view to identifying signatures of protective immunity and delineating the molecular mechanisms of vaccine immunity. Among these, influenza vaccines are the most studied [7, [9] [10] [11] [12] 15] . Our group compared the [7] . Although LAIV, which is given intranasally by spray, was not able to induce robust antibody response in the serum of vaccinees, a strong induction of antiviral type I interferon genes was detected in the blood [7] , suggesting that immune cells primed in nasal mucosa circulate in the blood or activate other blood immune cells. Vaccination with TIV, however, does induce a robust expansion of antibody-secreting plasma cells (the magnitude peaking at approximately day 7) in the blood of vaccinees [6] , which is reflected by gene signatures associated with antibody production and plasma B cell differentiation [7] . At an earlier time point, even with no virus replication, TIV elicits signatures associated with innate immunity, such as interferon and inflammatory responses [7] . Others also found similar results in adults [11, 12] and even in children [15] .
Despite these important observations, a critical question posed by all these studies is to what extent can the signatures obtained in a given study be used broadly to predict vaccine immunity induced by vaccination in multiple influenza seasons and in diverse populations such as those at the extremes of age? This is a critical question, because influenza viruses are constantly changing in small ('antigenic drift') or major ('antigenic shift') ways. Furthermore, no transcriptional signatures were developed to predict the longevity of the antibody responses 6-12 months post-vaccination. This is important, because a major issue with the influenza vaccine is the waning immunity against vaccination.
An increasing number of studies have attempted to analyse and integrate data from different levels of molecular information [9, [34] [35] [36] . Franco et al. [9] searched for genetic and transcriptional components associated with the magnitude of antibody immune response to influenza vaccination. Through genome-wide single nucleotide polymorphism genotyping and transcriptional profiling, they were able to map expression quantitative trait loci (eQTL) that could be important determinants of vaccine immunogenicity [9] . Lee et al. [34] performed an integrative approach, which combines transcriptomic and metabolomic data to evaluate the impact of an anti-malarial drug on the blood, bone marrow and plasma of rhesus macaques. However, such approaches have not yet been applied to characterize vaccine-induced immunity in humans. Our group is analysing both the transcriptomic and metabolomic profiles of young adults and elderly populations vaccinated with varicella zoster virus vaccine [37] . This integrative approach will provide new insights about the fundamental mechanisms of immunity.
Although the analysis of multi-omics experiments holds great promises for achieving higher biological knowledge, it also poses a tremendous challenge for computational biologists. The difficulties in modelling the natural complexity of multiple layers of regulation (chromatin regions, RNA molecules, proteins, metabolites) rely on (i) the inherent heterogeneity of an individual response over different time rstb.royalsocietypublishing.org Phil. Trans. R. Soc. B 370: 20140146 points (longitudinally) [36] , as well as the differences on genetics, previous immunological events, microbiota or environment across populations; (ii) the intrinsic noise of high-throughput technologies and (iii) the stochasticity of molecular processes [28] . With the concomitant decrease in costs and the increase in power, sensitivity and specificity of 'omics' technologies, combined with new approaches [38] and genome editing [39] , relatively small laboratories will soon be able to generate massive amount of data (figure 2). Several databases and tools are already available to, respectively, store and analyse 'single omics' data [36] , but very few computational programs and models exist to truly integrate more than one type of 'omics' data. More importantly, bioinformaticians will need to work very closely with immunology experts in order to transform high-throughput analyses into concrete knowledge, and ultimately, understanding (figure 2).
Recent tools and developments
Biological processes are carried out in a modular manner, where sets of molecules (e.g. RNA transcripts and proteins) work together to achieve specific functions [26] . These molecules interact with each other functionally or physically and are often coordinately expressed within the cell. Therefore, systems analyses should focus on subtle changes in the networks formed by these interacting molecules rather than on small numbers of highly differentially expressed genes [27] . Based on this idea, Tan et al. [27] built models from sets of biologically related genes that were able to predict antibody responses to TIV vaccination with high accuracies for both training and testing sets. The predictive sets of coordinately expressed genes were related to B cell biology and proliferation, therefore capturing the cellular changes in antibody secreting plasma cell seen in the blood of TIV vaccinees on day 7 post-vaccination [27] . More importantly, it demonstrates that, in addition to its sensitivity and robustness, this gene-set-based approach can put results into biological context [27] .
One of the major problems, however, in using current gene set databases for systems vaccinology analyses is that they are limited in immunological pathways. Although InnateDB [40] , MSigDB [41] and Ingenuity (http://www.ingenuity.com/) databases contain some manually annotated genes and pathways related to immune functions, most of the commonly used pathway databases (KEGG [42] , NCI-PID [43] , Reactome [44] , Biocarta (http://www.biocarta.com/)) are biased toward oncology and non-immunological diseases [45] . Those gene sets that are indeed immune-related were usually defined by 'extreme' biological conditions, such as acute infections or autoimmune diseases. Comparatively to these conditions, vaccination (even with live attenuated organisms) represents a 'mild perturbation' in the transcriptome of individuals. In addition, not all genes from a given gene set are transcriptionally synchronized, neither are they are all expressed in blood. Thus, analyses based on gene overlap enrichment [46] or on the positional test gene set enrichment analysis framework [47] , which use gene sets previously defined by current databases may not be ideal for systems vaccinology, as only a small and specific fraction of the genes from these sets may be affected by vaccination.
To circumvent this issue, we have developed our own gene modules and used them to compare the transcriptional signatures elicited by five different vaccines [17] . In order to identify modules specifically expressed in the blood, we analysed co-expression relationships between genes in more than 30 000 transcriptional profiles from approximately 500 published blood-related studies. This procedure generated a huge 'master network' containing 17 000 þ genes and 600 000 þ connections (i.e. co-expression). Next, we extracted 334 modules composed of highly connected genes with specific biological contexts [17] (figure 3). Each 'blood transcriptional module' (BTM) was then manually annotated according to its genes and their functions. We compared the transcriptional activity of BTMs in the PBMC profiles of subjects vaccinated with yellow fever (YF-17D), influenza (LAIV and TIV) or meningococcal (MCV4 and MPSV4) vaccines to find unique and common patterns of vaccineinduced immunity [17] . Applying the BTM framework, we [17] 260 sets of co-clustered genes [48] http://www.immuneprofiling.org Figure 3 . Gene modules available for systems vaccinology studies. Three sets of gene modules which are useful for blood transcriptomics. Each set was constructed using different strategies and methodologies.
rstb.royalsocietypublishing.org Phil. Trans. R. Soc. B 370: 20140146 observed that the blood transcriptional profiling of subjects receiving MCV4, which is a vaccine containing polysaccharide conjugated with diphtheria toxoid (DT) protein, yielded two sets of correlation profiles: one for the DT antibody response, and one for the polysaccharide antibody response [17] . Additionally, this framework allowed us to correlate for the first time, to the best of our knowledge, the expression of type I interferon genes with the antibody response induced by YF-17D vaccination [17] . Thus, our BTMs represent a powerful new resource for systems vaccinology studies.
Other groups have also developed gene sets that are valuable for systems vaccinology analyses ( figure 3 ). Using the K-means algorithm to cluster genes with similar expression patterns in multiple disease datasets, Chaussabel et al. [48] identified 28 transcriptional PBMC modules that were applied to systemic lupus erythematosus. These gene sets were later expanded and used to study the human blood transcriptional changes induced by virus [49] and bacterial [50, 51] infections as well as vaccination [12] . The 'immunologic signatures' collection of MSigDB [52] contains gene sets representing a broad range of cell states and perturbations within the immune system. As additional studies are being incorporated in this procedure, the collection of gene sets available for blood transcriptomics may continuously increase.
Dedicated databases and user-friendly webtools will soon become essential for immunologists and computational biologists to manage, integrate and analyse high-throughput data. The Immunology Database and Analysis Portal (ImmPort) system was created towards these goals, and now contains approximately 100 datasets publicly available for download and re-analysis [53] . As more studies are progressively uploaded into ImmPort, immunology research will advance in a collaborative, transparent and reproducible way.
Biological insights emerging from systems vaccinology
An integral part of systems vaccinology is the development and testing of new insights and the generation of datadriven hypotheses (figure 2). To achieve this, computational scientists must work closely with immunologists, and both teams should be able to comprehend and to communicate with each other effectively. The technical expertise and analytical vision of computational scientists in mining databases, developing tools and performing the right statistical tests complement the biology-driven quests and abstraction of immunologists in proposing mechanistic studies, and planning and executing the experiments necessary for validating the hypotheses. One of these insights arose from our efforts to identify innate blood gene signatures that are able to predict the magnitude of the later CD8 þ T cell response to YF-17D
vaccination [16] . Among the genes on these predictive signatures, we found the kinase known as GCN2 (EIF2AK4), a key player in the so-called integrated stress response [54] . The integrated stress response is an evolutionarily ancient mechanism that can sense a diverse range of stress-inducing stimuli (such as amino acid starvation, endoplasmic reticulum stress, etc.) [55] . In mammals, GCN2 responds to amino acid starvation by triggering phosphorylation of eukaryotic translation initiation factor 2a (eIF2a) [56] , which, in turn, shuts down translation, resulting in stress granule formation in the cell. We wondered why such an ancient gene would be involved with human adaptive immune responses. Using liquid chromatography/mass spectrometry, we were able to show that YF-17D decreases the intracellular concentration of certain free amino acids. Interestingly, both CD4 þ and CD8 þ T cell responses were reduced in deficient mice [30] . We have also shown, using mice deficient to other genes in GCN2 pathway as well, that the YF-17D-induced T cell responses involve initiation of autophagy and enhanced antigen presentation by DCs to T cells, demonstrating a role for GCN2 in the induction of T cell immunity to YF-17D [30] . This highlights a novel role for the evolutionarily ancient integrated stress response in modulating dendritic cell function and adaptive immunity. Another gene whose early expression correlated with TIV immunogenicity was the Toll-like receptor 5 (TLR5) [7] . The natural ligand of TLR5 is flagelin, a major flagella component found in many bacteria [57] , including those that inhabit human gut. The direct correlation between the expression of TLR5 at day 3 post-TIV vaccination with the antibody response one month later [7] indicated that our microbiota could help boost the immunity induced by a vaccine, even one against a virus. To test this hypothesis, we immunized TLR5-deficient mice, as well as mice treated with antibiotics and germ-free mice, with TIV and compared their antibody responses with antibody response wild-type germ-free wild-type wild-type + antibiotics TLR5 -/- [7] [29]
antibody response (day 30)
TLR5 expression (day 3 post-TIV) Figure 4 . Insight about the role of microbiota in vaccine-induced immunity. Our systems vaccinology study on seasonal trivalent influenza vaccine (TIV) [7] found that the expression of Toll-like receptor 5 (TLR5) was directly correlated with antibody responses to TIV, raising the hypothesis that microbiota play a role on TIV induced immunity. This hypothesis was tested and validated in a subsequent study [29] , demonstrating that new and interesting insights can emerge from systems vaccinology work.
rstb.royalsocietypublishing.org Phil. Trans. R. Soc. B 370: 20140146 those induced by wild-type mice [29] (figure 4). As the magnitude of antibody response was significantly lower in TLR5-deficient mice and mice with fewer bacteria in the gut, we showed that mirobiota are crucial for the rapid induction of vaccine-induced antibody responses [29] . We also characterized the microbiome of untreated and antibiotic-treated mice and found that multiple classes of bacteria are necessary to impact B cell responses to TIV [29] . Finally, we evaluated the impact of microbiota on the immune responses to several types of vaccines, including a live attenuated virus vaccine (YF-17D), an alum-toxoid adjuvanted vaccine (against tetanus-diphtheria-pertussis), and another unadjuvanted protein vaccine (against polio) [29] . Among them, only the vaccine against polio exhibited differences in magnitudes of antibody responses between untreated and antibiotic-treated mice, suggesting that dependence on microbiota is greater for inactivated vaccines containing weak or no adjuvants [29] . These results demonstrate the impact of the microbiome on immunity to vaccination. Future studies should thus integrate data from analysis of the microbiome in identifying correlates of immunity to vaccination.
Ongoing studies and future directions
Although systems vaccinology has been extensively applied to study immune responses to TIV influenza vaccination in young adults [7, [9] [10] [11] , very little has been done to investigate such responses in extreme age groups such as young children and the elderly [58] , which have suboptimal responses to TIV vaccination [59, 60] . In our work, in collaboration with Advanced Immunization Technologies, we are identifying early signatures of TIV immunogenicity in children of less than 2 years of age [61] . Additionally, we performed a comprehensive set of immunological and high-throughput analyses on elderly populations (more than 65 years old), including microRNA and gene expression profiling, to assess the mechanisms of immunosenescent responses to TIV and to verify if the signatures that predict antibody responses in young adults [7] can also be used to predict elderly responses [61] . These studies (figure 5) may offer new insights about efficacy of TIV in people at extremes of age and provide useful information for the rational design of novel vaccines or strategies that target these populations. Integration of metabolomics, i.e. the profiling of metabolites, into models of vaccine immunity can help reveal the link between gene pathways and biological mechanisms. Although many metabolites are being progressively identified as important mediators of immune response [62] [63] [64] [65] [66] , there is still no study using metabolomics to assess vaccineinduce immunity in human vaccinated cohorts. In our ongoing work, we performed transcriptomics on PBMCs and high-resolution metabolomics on plasma samples from a varicella zoster virus (VSV; shingles) vaccination cohort. One striking observation was that while only few genes had their expression altered 1 day after vaccination, the level of a large number of metabolites changed after vaccination [37] . In later time points, this pattern is inverted, and the expression of many genes is altered after vaccination. Investigating the interplay between metabolic modulators and biological pathways will bring interesting insights about the molecular mechanism underlying the immune response to VZV vaccine.
Metabolomics can also be applied to identify signatures of vaccine immunity. The perspective in finding such markers using samples obtained by non-invasive methods (e.g. urine and saliva) is astonishing. This would be especially important to assess biofluid samples from neonates and infants during their routine immunization schedule. However, major challenges need to be overcome in order to identify reliable metabolite surrogates for vaccine immunogenicity or protection. They include difficulties in metabolite annotation, intrinsic noise of metabolomics platforms and reproducibility issues associated with lack of proper clinical phenotyping [67] , inherent heterogenity of individuals, differences in kinetics and/or small sample size [68] .
Finally, an important application of systems approaches is to define correlates of protection in clinical trials. Currently, the only way of determining correlates in clinical trials is to perform retrospective, nested case controlled analysis of immune responses [2, 69] . However, this involves the analysis of thousands of subjects, which should be then retrospectively selected based on their challenge outcome or immunological responses to vaccination. work, time and money spent on this process can be prohibitive for most research groups. A complementary approach to this issue is to use infection-inducing 'challenge models' in humans to define correlates of protection. The ability to conduct such infection-inducing challenge studies, in a safe and ethical manner, provides unprecedented opportunities to determine correlates of protection induced by vaccination against diseases such as malaria [70, 71] , cholera [72] , influenza [73] and typhoid [74, 75] . In this context, a previous study has used systems approaches to define molecular signatures that correlate with protection induced by the RTS,S/AS01 vaccine against P. falciparum infection in humans [76] . For that, they assessed the genome-wide expression changes induced after the third vaccination dose, but not at earlier time points (i.e. after the first or second doses) [76] . Future studies should use systems biological approaches to characterize the magnitude, quality and kinetics of the innate and adaptive responses to the RTS,S vaccine in greater detail, with a view to identifying signatures that accurately predict efficacy (figure 6). However, the effective use of systems approaches in identifying correlates of immunity and efficacy in clinical trials requires harmonization (if not standardization) of biological sample collection and storage, as well as processing and analysis between studies and sites. The need to cross-validate studies is clearly of paramount importance in the identification of robust signatures that can be used to predict vaccine efficacy in clinical trials. These exciting advances highlight the potential of systems biology to transform vaccine design and development. Using systems approaches to identify molecular signatures that can be used to predict vaccine efficacy in clinical trials will greatly accelerate the testing of vaccines. Furthermore, the novel biological insights provided by such studies will greatly enhance our understanding of the mechanisms underlying vaccine immunity and, immune regulation in general.
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